Adaptimmune Therapeutics
ADAP
#9324
Rank
A$0.10 B
Marketcap
$0.43
Share price
-20.31%
Change (1 day)
-79.49%
Change (1 year)

Revenue for Adaptimmune Therapeutics (ADAP)

Revenue in 2024 (TTM): A$0.26 Billion

According to Adaptimmune Therapeutics's latest financial reports the company's current revenue (TTM ) is A$0.29 Billion. an increase over the revenue in the year 2023 that were of A$88.47 Million. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Adaptimmune Therapeutics from 2016 to 2024

Annual revenue

Year Revenue Change
2024 A$0.28 B223.49%
2023 A$88.47 M121.79%
2022 A$39.89 M370.36%
2021 A$8.48 M64.77%
2020 A$5.14 M221.2%
2019 A$1.6 M-98.1%
2018 A$84.46 M74.3%
2017 A$48.46 M146.03%
2016 A$19.69 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
A$1.12 B 283.17%๐Ÿ‡บ๐Ÿ‡ธ USA
A$48.12 M-83.66%๐Ÿ‡บ๐Ÿ‡ธ USA
A$37.51 M-87.26%๐Ÿ‡ณ๐Ÿ‡ฑ Netherlands
A$3.58 B 1,118.15%๐Ÿ‡บ๐Ÿ‡ธ USA